# A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

> clinical trial · VERIFIED · 2026-07-02

Status: RECRUITING · Sponsor: Nurix Therapeutics, Inc. · Condition: Chronic Lymphocytic Leukemia (CLL)

- Company: Nurix Therapeutics, Inc.
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT07221500

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.